See more : Aston Martin Lagonda Global Holdings plc (ARGGY) Income Statement Analysis – Financial Results
Complete financial analysis of Fennec Pharmaceuticals Inc. (FENC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fennec Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Urban Jakarta Propertindo Tbk. (URBN.JK) Income Statement Analysis – Financial Results
- SBEC Sugar Limited (SBECSUG.BO) Income Statement Analysis – Financial Results
- Opple Lighting Co.,LTD (603515.SS) Income Statement Analysis – Financial Results
- Speciality Restaurants Limited (SPECIALITY.BO) Income Statement Analysis – Financial Results
- Sanso Electric Co.,Ltd. (6518.T) Income Statement Analysis – Financial Results
Fennec Pharmaceuticals Inc. (FENC)
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.25M | 1.54M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.68 |
| Cost of Revenue | 1.26M | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -55.23K | 0.00 |
| Gross Profit | 19.99M | 1.45M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.23K | 0.68 |
| Gross Profit Ratio | 94.08% | 94.40% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8,359,700.00% | 100.00% |
| Research & Development | 56.00K | 3.53M | 4.98M | 5.11M | 5.61M | 5.01M | 1.94M | 472.00K | 256.00K | 357.00K | 597.00K | 2.08M | 1.49M | 708.00K | 2.11M | 10.37M | 10.91M | 14.00M | 12.44M | 3.59M | 3.55M | 3.13M | 1.91M | 939.36K |
| General & Administrative | 20.59M | 17.72M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.12M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.71M | 20.51M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 1.94M | 3.90M | 1.21M | 3.52M | 3.28M | 2.88M | 3.18M | 3.49M | 1.78M | 907.40K | 738.72K | 614.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.00K | -17.00K | 6.00K | -8.00K | -14.00K | 0.00 | 0.00 | -3.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18M | 2.72M | 2.34M | 1.42M | 0.00 | 55.23K | 52.01K |
| Operating Expenses | 32.76M | 24.04M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.70M | 1.61M |
| Cost & Expenses | 34.06M | 24.12M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.65M | 1.61M |
| Interest Income | 441.00K | 195.00K | 54.00K | 87.00K | 322.32K | 0.00 | 0.00 | 0.00 | 3.00K | 2.00K | 2.00K | 25.00K | 43.00K | 32.00K | 47.00K | 286.00K | 833.00K | 0.00 | 361.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.39M | 978.00K | 126.00K | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00K | 11.00K | -444.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.00K | 149.00K | 17.22M | 402.00K | 13.01M | 10.41M | 6.95M | 2.87M | -1.23M | -699.00K | -1.00K | 20.00K | 43.00K | 3.25M | 615.00K | 164.00K | 192.00K | 2.43M | 3.06M | 2.52M | 1.61M | 123.76K | 55.23K | 52.01K |
| EBITDA | -12.36M | -22.59M | -123.00K | -17.89M | 234.00K | 521.00K | -95.00K | 82.00K | -1.89M | -2.88M | 1.79M | -5.18M | 4.55M | -4.60M | -2.60M | -13.89M | -14.19M | -17.91M | -19.27M | -12.56M | -5.22M | -4.24M | -2.79M | -2.59M |
| EBITDA Ratio | -58.18% | -1,468.60% | 0.00% | -10,579.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -421,928,118.14% | -231,162,432.56% |
| Operating Income | -12.77M | -22.59M | -17.22M | -17.89M | -13.01M | -10.41M | -6.95M | -2.87M | -1.89M | -2.88M | -1.93M | -3.62M | -3.44M | -4.60M | -3.22M | -13.89M | -14.19M | -19.06M | -18.35M | -9.42M | -6.74M | -4.04M | -2.65M | -1.61M |
| Operating Income Ratio | -60.09% | -1,471.60% | 0.00% | -10,520.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -400,900,112.25% | -237,629,943.17% |
| Total Other Income/Expenses | -3.27M | -1.13M | -123.00K | -224.00K | 234.00K | 521.00K | -95.00K | 82.00K | 1.28M | 701.00K | 3.78M | -1.54M | 8.12M | -3.51M | 204.00K | 0.00 | 905.96K | -1.54M | -3.99M | -227.00K | 79.44K | 321.36K | 194.17K | 8.31K |
| Income Before Tax | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -20.64M | -21.54M | -9.59M | -6.67M | -3.72M | -2.45M | -1.60M |
| Income Before Tax Ratio | -75.50% | -1,544.89% | 0.00% | -10,652.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| Income Tax Expense | 0.00 | 1.13M | 110.00K | -187.00K | -315.00K | -348.00K | -47.00K | -8.00K | -3.00K | -2.00K | -2.00K | -25.00K | -43.00K | 7.82M | 3.01M | 13.60M | 13.36M | -1.54M | -2.29M | -854.68K | -518.20K | 3.72M | 2.45M | 1.60M |
| Net Income | -16.05M | -24.84M | -17.46M | -17.92M | -12.46M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -19.10M | -19.25M | -8.74M | -6.15M | -3.72M | -2.45M | -1.60M |
| Net Income Ratio | -75.50% | -1,618.18% | 0.00% | -10,542.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| EPS | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.19 | -0.63 | 0.59 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -20.12 | -2.98 |
| EPS Diluted | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.17 | -0.62 | 0.58 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -4.04 | -2.98 |
| Weighted Avg Shares Out | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 18.94M | 14.99M | 12.68M | 10.83M | 9.87M | 9.72M | 8.20M | 7.99M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 122.02K | 536.64K |
| Weighted Avg Shares Out (Dil) | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 19.02M | 15.01M | 12.77M | 10.83M | 9.87M | 10.57M | 8.39M | 8.02M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 607.09K | 536.64K |
FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 2, 2020 in the Class Action Filed on Behalf of Fennec Pharmaceuticals Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) alleging that the Company violated federal securities...
FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action - FENC
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. between February 11, 2020 and August 10, 2020, inclusive (the "Class Period"), of the important...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 2, 2020 - FENC
New York, New York--(Newsfile Corp. - November 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) ("Fennec") between February 11,...
FENC Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Lead Plaintiff Deadline: November 2, 2020
New York, New York--(Newsfile Corp. - November 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers,...
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceuticals Inc. ("Fennec" or "the Company") (NASDAQ: FENC) for violations of...
FENC Final Deadline Alert: Rosen, Top Ranked Global Counsel, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - FENC
New York, New York--(Newsfile Corp. - October 30, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 and August 10, 2020, inclusive (the...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
LOS ANGELES--(BUSINESS WIRE)---- $FENC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Fennec Pharmaceuticals Inc....
FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 2, 2020 in the Class Action Filed on Behalf of Fennec Pharmaceuticals Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - October 30, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) alleging that the Company violated federal securities...
DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceuticals Inc. (NASDAQ: FENC) ("Fennec" or "the Company") for violations of...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 2, 2020 - FENC
New York, New York--(Newsfile Corp. - October 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fennec Pharmaceuticals Inc. ("Fennec") (NASDAQ: FENC) between February...
Source: https://incomestatements.info
Category: Stock Reports